Partners

Tetra is actively seeking potential commercial partners for our two drug programs, PDE4D and PDE4B inhibitors, as well as Fragile X Syndrome; Alzheimer’s disease; schizophrenia/cognition; and traumatic brain injury drug projects. In partnerships, we seek to effectively leverage Tetra’s drug discovery platform and know-how with the clinical translation expertise of the pharma partner. We are also interested in novel therapeutic opportunities linking phosphodiesterases to other peripheral as well as central diseases.

MEDICINES FOR ALZHEIMER’S DISEASE

Dr. James M. O’Donnell is Dean of the School of Pharmaceutical Sciences of SUNY-Buffalo.

MEDICINES FOR FRAGILE X SYNDROME

The Fraxa Foundation

Michael Tranfaglia, MD is Medical Director and Chief Scientific Officer of the Fraxa Foundation.

Frauenhofer Institute

Dr. Patricia Cogram

MEDICINES FOR TRAUMATIC BRAIN INJURY

The Miami Project to Cure Paralysis / University of Miami Health System

Coleen Atkins PhD

W. Dalton Dietrich PhD

COMMERCIALIZATION OF BPN14770

Shionogi & Co. Ltd., strategically collaborating for the clinical development and commercialization of BPN14770, Tetra’s selective phosphodiesterase-4D (PDE4D) allosteric inhibitor.

If you are interested in partnering with Tetra, please contact info@tetradiscovery.com.